Windtree Therapeutics Files 8-K on Financials
Ticker: WINTW · Form: 8-K · Filed: Aug 20, 2024 · CIK: 946486
| Field | Detail |
|---|---|
| Company | Windtree Therapeutics Inc /De/ (WINTW) |
| Form Type | 8-K |
| Filed Date | Aug 20, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, 8-K, operations
Related Tickers: WINT
TL;DR
WINT filed an 8-K on Aug 20th covering financial results and exhibits.
AI Summary
Windtree Therapeutics, Inc. filed an 8-K on August 20, 2024, reporting on its results of operations and financial condition, and including financial statements and exhibits. The filing pertains to the company's ongoing business operations and financial disclosures.
Why It Matters
This filing provides investors with crucial updates on Windtree Therapeutics' financial health and operational performance, impacting investment decisions.
Risk Assessment
Risk Level: low — This is a routine financial disclosure filing and does not indicate any immediate or significant risks.
Key Players & Entities
- WINDTREE THERAPEUTICS INC /DE/ (company) — Registrant
- August 20, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 001-39290 (identifier) — Commission File Number
- 94-3171943 (identifier) — I.R.S. Employer Identification No.
- 2600 Kelly Road, Suite 100, Warrington, Pennsylvania 18976 (address) — Business address
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on Windtree Therapeutics, Inc.'s results of operations and financial condition, and to include financial statements and exhibits.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on August 20, 2024.
In which state is Windtree Therapeutics, Inc. incorporated?
Windtree Therapeutics, Inc. is incorporated in Delaware.
What is the company's Commission File Number?
The company's Commission File Number is 001-39290.
What is the business address of Windtree Therapeutics, Inc.?
The business address of Windtree Therapeutics, Inc. is 2600 Kelly Road, Suite 100, Warrington, Pennsylvania 18976.
Filing Stats: 558 words · 2 min read · ~2 pages · Grade level 10.5 · Accepted 2024-08-20 16:30:55
Key Financial Figures
- $0.001 — h registered Common Stock , par value $0.001 per share WINT The Nasdaq Capital M
Filing Documents
- wint20240529_8k.htm (8-K) — 31KB
- ex_680953.htm (EX-99.1) — 166KB
- logo.jpg (GRAPHIC) — 7KB
- 0001437749-24-027380.txt ( ) — 351KB
- wint-20240820.xsd (EX-101.SCH) — 3KB
- wint-20240820_def.xml (EX-101.DEF) — 11KB
- wint-20240820_lab.xml (EX-101.LAB) — 15KB
- wint-20240820_pre.xml (EX-101.PRE) — 11KB
- wint20240529_8k_htm.xml (XML) — 3KB
02
Item 2.02 Results of Operations and Financial Condition On August 20, 2024, Windtree Therapeutics, Inc. (the "Company") issued a press release announcing its financial results for the quarter ended June 30, 2024 . A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information contained in this Item 2.02 (including Exhibit 99.1) is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section and shall not be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Financial Statements and Exhibits
Financial Statements and Exhibits (d) Exhibits The following exhibits are being filed herewith: Exhibit No. Document 99.1 Press Release of Windtree Therapeutics, Inc., dated August 20, 2024 announcing financial results for the quarter ended June 30, 2024, furnished herewith. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Windtree Therapeutics, Inc. By: /s/ Craig E. Fraser Name: Craig E. Fraser Title: President and Chief Executive Officer Date: August 20, 2024